Herpes Simplex - Market Insight, Epidemiology and Market Forecast - 2027

  • ID: 4520737
  • Drug Pipelines
  • 169 pages
  • DelveInsight
UP TO OFF
until Dec 31st 2018
1 of 4

FEATURED COMPANIES

  • AiCuris - BioAlliance
  • Beech Tree Labs - Mylan
  • Maruho - GlaxoSmithKline
  • Squarex - Novartis
  • MORE
This report titled ‘Herpes Simplex Virus (HSV) Infections - Market Insights, Epidemiology and Market Forecast-2027’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of HSV infections in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of HSV infections from 2016 to 2027 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered:
  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan
Study Period: 2016-2027

HSV infections - Disease Understanding and Treatment Algorithm
The HSV infections market report gives the thorough understanding of HSV infections by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for HSV infections in the US, Europe, and Japan.

HSV infections Epidemiology:

The HSV infections epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [total prevalent cases, prevalent cases by types (Genital Herpes and Herpes Labialis), diagnosed prevalence] of HSV infections in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2016-2027.
According to this research, total prevalent population of HSV infections in 7 major markets were estimated to be 228,552,199 in 2016.

HSV Infections Drug Chapters:

This segment of the HSV infections report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

The current HSV Virus infections market is dependent on antiviral drugs that are not the cure of the disease but relief the symptoms of the disease and in long-term reduces the incidence of relapses if started before exposure to the triggering conditions. Although, antiviral therapies have proven its effectiveness in this market associated complications and need of a cure demands the emergence of novel therapy. Detailed chapter for upcoming therapies Pritelivir (AiCuris), SQX770 (Squarex), BTL TML HSV (Beech Tree Labs), GEN 003 (Genocea Biosciences), VCL-HB01 (Vical) and M5210B (Maruho) have been covered in the report.

HSV Infections Market Outlook:

The HSV Infections market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to this research, the market of HSV Infections in 7MM was found to be USD 4 Billion in 2016, and is expected to increase from 2016-2027.

HSV Infections Drugs Uptake:

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

HSV Infections Report Insights:
  • Patient Population
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies
HSV Infections Report Key Strengths:
  • 10 Year Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition
HSV Infections Report Assessment:
  • Current Treatment Practices
  • Unmet Needs
  • Detailed Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers
Key Benefits:
  • This report will help to develop Business Strategies by understanding the trends shaping and driving HSV Infections market
  • Organize sales and marketing efforts by identifying the best opportunities for HSV Infections market
  • To understand the future market competition in the HSV Infections market.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AiCuris - BioAlliance
  • Beech Tree Labs - Mylan
  • Maruho - GlaxoSmithKline
  • Squarex - Novartis
  • MORE
1. Key Insights

2. Herpes Simplex Virus Market Overview at a Glance
2.1. Market Share (%) Distribution of Herpes Simplex Virus in 2016
2.2. Market Share (%) Distribution of Herpes Simplex Virus in 2027

3. Disease Background and Overview: Herpes Simplex Virus (HSV)
3.1. Introduction
3.2. Stages of Herpes infection
3.3. Clinical manifestations
3.4. Risk Factors
3.5. Disease Causes
3.6. HSV-Symptoms
3.7. Pathogenesis
3.8. HSV Diagnosis

4. Epidemiology and Patient Population

5. Key Findings
5.1. Disease Definition
5.2. Population and Forecast Parameters
5.3. 7MM Prevalent Population of Herpes Simplex Virus (HSV)
5.4. 7MM Type-Specific Prevalent Population of Herpes Simplex Virus (HSV)

6. Country Wise-Epidemiology of Herpes Simplex Virus (HSV)
6.1. United States
6.1.1. Prevalent Population of HSV in the United States
6.1.2. Type-Specific HSV Prevalence in the United States
6.1.3. Diagnosed Cases of HSV in the United States
6.2. Germany
6.2.1. Prevalent Population of HSV in Germany
6.2.2. Type-Specific HSV Prevalence in Germany
6.2.3. Diagnosed Cases of HSV in Germany
6.3. France
6.3.1. Prevalent Population of HSV in France
6.3.2. Type-Specific HSV Prevalence in France
6.3.3. Diagnosed Cases of HSV in France
6.4. Italy
6.4.1. Prevalent Population of HSV in Italy
6.4.2. Type Specific HSV prevalence in Italy
6.4.3. Diagnosed cases of HSV in Italy
6.5. Spain
6.5.1. Prevalent Population of HSV in Spain
6.5.2. Type Specific HSV prevalence in Spain
6.5.3. Diagnosed cases of HSV in Spain
6.6. United Kingdom
6.6.1. Prevalent cases of HSV in the UK
6.6.2. Type Specific HSV prevalence in the UK
6.6.3. Diagnosed cases of HSV in the UK
6.7. Japan
6.7.1. Prevalent cases of HSV in Japan
6.7.2. Type Specific HSV prevalence in Japan
6.7.3. Diagnosed cases of HSV in Japan

7. Treatment Algorithm
7.1. Centers for Disease Control and Prevention (CDC): Guidelines for the treatment of Genital Herpes
7.2. WHO Recommendations for Treatment of Genital Herpes Simplex Virus
7.3. 2017 European Guidelines for Management of Genital Herpes

8. Unmet needs

9. Marketed drugs
9.1. Abreva: GSK/Avanir Pharmaceuticals
9.1.1. Drug Description
9.1.2. Regulatory Milestones
9.1.3. Advantages & Disadvantages
9.1.4. Product Profile
9.2. Viroptic Opthalmic Solution (trifluridine) 1%: Pfizer Inc.
9.2.1. Drug Description
9.2.2. Regulatory Milestones
9.2.3. Advantages & Disadvantages
9.2.4. Safety and Efficacy
9.2.5. Product Profile
9.3. Famvir: Novartis
9.3.1. Drug Description
9.3.2. Other development activities
9.3.3. Regulatory Milestones
9.3.4. Advantages & Disadvantages
9.3.5. Safety and Efficacy
9.3.6. Product Profile
9.4. Valtrex: GlaxoSmithKline
9.4.1. Drug Description
9.4.2. Other development activities
9.4.3. Regulatory Milestones
9.4.4. Advantages & Disadvantages
9.4.5. Safety and Efficacy
9.4.6. Product Profile
9.5. Denavir: Mylan Pharmaceuticals
9.5.1. Drug Description
9.5.2. Regulatory Milestones
9.5.3. Advantages & Disadvantages
9.5.4. Safety and Efficacy
9.5.5. Product Profile
9.6. Foscavir: Clinigen Group Plc.
9.6.1. Drug Description
9.6.2. Regulatory Milestones
9.6.3. Advantages & Disadvantages
9.6.4. Safety and Efficacy
9.6.5. Product Profile
9.7. Sitavig/Sitavir: BioAlliance Pharma
9.7.1. Drug Description
9.7.2. Regulatory Milestones
9.7.3. Advantages & Disadvantages
9.7.4. Safety and Efficacy
9.7.5. Product Profile
9.8. Zovirax: GlaxoSmithKline
9.8.1. Drug Description
9.8.2. Regulatory Milestones
9.8.3. Advantages & Disadvantages
9.8.4. Safety and Efficacy
9.8.5. Product Profile
9.9. Lipsovir: Medivir
9.9.1. Drug Description
9.9.2. Regulatory Milestones
9.9.3. Advantages & Disadvantages
9.9.4. Safety and Efficacy
9.9.5. Product Profile

10. Emerging Therapies

11. Key Cross Competition

12. Phase II/III Drugs
12.1. SQX770: Squarex
12.1.1. Drug Description
12.1.2. Product Profile
12.1.3. Clinical Development
12.1.4. Clinical Trials Information
12.2. BTL TML HSV: Beech Tree Labs
12.2.1. Drug Description
12.2.2. Product Profile
12.2.3. Other Development Activities
12.2.4. Clinical Development
12.2.5. Clinical Trials Information
12.2.6. Safety and Efficacy
12.2.7. Advantages and Disadvantages
12.3. GEN 003: Genocea Biosciences
12.3.1. Drug Description
12.3.2. Product Profile
12.3.3. Other Development Activities
12.3.4. Clinical Development
12.3.5. Clinical Trials Information
12.3.6. Safety and Efficacy
12.3.7. Advantages and Disadvantages
12.4. Pritelivir: AiCuris
12.4.1. Drug Description
12.4.2. Product Profile
12.4.3. Regulatory Milestones
12.4.4. Clinical Development
12.4.5. Clinical Trials Information
12.4.6. Safety and Efficacy
12.4.7. Advantages and Disadvantages
12.5. VCL-HB01: Vical
12.5.1. Drug Description
12.5.2. Product Profile
12.5.3. Other Development Activities
12.5.4. Clinical Development
12.5.5. Clinical Trials Information
12.5.6. Safety and Efficacy
12.5.7. Advantages and Disadvantages
12.6. M5210B: Maruho
12.6.1. Drug Description
12.6.2. Product Profile

13. Herpes Simplex Virus (HSV) Infection: Market Analysis
13.1. Key Findings
13.2. Herpes Simplex Virus (HSV) Infections: Total Market Size in 7MM
13.3. Total Market Size of HSV Infection in 7MM
13.4. Market size of HSV Infection by Clinical Manifestations in 7MM
13.5. EmergingTherapy-based Market Size of HSV Infection in 7MM

14. Market Size of HSV by Country
14.1. United States Market Analysis
14.1.1. Market Size of HSV Infection in the US
14.1.2. Market size of HSV Infection by Clinical Manifestations in the US
14.1.3. Treatment Type & Therapy Based Market Size of HSV Infection
14.1.4. Herpes Simplex Virus Infections Market by Emerging Therapies
14.2. Herpes Simplex Virus: EU5 Market Outlook
14.3. Germany
14.3.1. Market Size of HSV Infection in Germany
14.3.2. Market size of HSV Infection by Clinical Manifestations in Germany
14.3.3. Treatment Type & Therapy Based Market Size of HSV
14.3.4. Herpes Simplex Virus Infections Market by Emerging Therapies
14.4. France
14.4.1. Market Size of HSV Infection in France
14.4.2. Market size of HSV by Clinical Manifestations in France
14.4.3. Treatment Type & Therapy Based Market Size of HSV Infection
14.4.4. Herpes Simplex Virus Infections Market by Emerging Therapies
14.5. Italy
14.5.1. Market Size of HSV Infection in Italy
14.5.2. Market size of HSV Infection by Clinical Manifestations in Italy
14.5.3. Treatment Type & Therapy Based Market Size of HSV Infection
14.5.4. Herpes Simplex Virus Infections Market by Emerging Therapies
14.6. Spain
14.6.1. Market Size of HSV Infection in Spain
14.6.2. Market size of HSV Infection by Clinical Manifestations in Spain
14.6.3. Treatment Type & Therapy Based Market Size of HSV Infection
14.6.4. Herpes Simplex Virus Infections Market by Emerging Therapies
14.7. United Kingdom
14.7.1. Market Size of HSV Infection in the UK
14.7.2. Market size of HSV Infection by Clinical Manifestations in UK
14.7.3. Treatment Type & Therapy Based Market Size of HSV Infection
14.7.4. Herpes Simplex Virus Infections Market by Emerging Therapies
14.8. Japan: Market Analysis
14.8.1. Market Size of HSV Infection in Japan
14.8.2. Market size of HSV Infection by Clinical Manifestations in Japan
14.8.3. Treatment Type & Therapy Based Market Size of HSV Infection
14.8.4. Herpes Simplex Virus Infections Market by Emerging Therapies

15. Market Drivers of HSV

16. Market Barriers of HSV

17. Appendix
17.1. Report Methodology

18. Capabilities

19. Disclaimer

20. About the Publisher

List of Tables
Table 1: Total Prevalent/Incident Cases of the Herpes Simplex in 7MM
Table 2: Total Prevalent/Incident Cases of the Herpes Simplex in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Herpes Simplex in United States (2016-2027)
Table 4: Sub-Type Specific cases of the Herpes Simplex in United States (2016-2027)
Table 5: Sex- Specific Cases of the Herpes Simplex in United States (2016-2027)
Table 6: Diagnosed Cases of the Herpes Simplex in United States (2016-2027)
Table 7: Treatable Cases of the Herpes Simplex in United States (2016-2027)
Table 8: Prevalent/Incident Cases of the Herpes Simplex in Germany (2016-2027)
Table 9: Sub-Type Specific cases of the Herpes Simplex in Germany (2016-2027)
Table 10: Sex- Specific Cases of the Herpes Simplex in Germany (2016-2027)
Table 11: Diagnosed Cases of the Herpes Simplex in Germany (2016-2027)
Table 12: Treatable Cases of the Herpes Simplex in Germany (2016-2027)
Table 13: Prevalent/Incident Cases of the Herpes Simplex in France (2016-2027)
Table 14: Sub-Type Specific cases of the Herpes Simplex in France (2016-2027)
Table 15: Sex- Specific Cases of the Herpes Simplex in France (2016-2027)
Table 16: Diagnosed Cases of the Herpes Simplex in France (2016-2027)
Table 17: Treatable Cases of the Herpes Simplex in France (2016-2027)
Table 18: Prevalent/Incident Cases of the Herpes Simplex in Italy (2016-2027)
Table 19: Sub-Type Specific cases of the Herpes Simplex in Italy (2016-2027)
Table 20: Sex- Specific Cases of the Herpes Simplex in Italy (2016-2027)
Table 21: Diagnosed Cases of the Herpes Simplex in Italy (2016-2027)
Table 22: Treatable Cases of the Herpes Simplex in Italy (2016-2027)
Table 23: Prevalent/Incident Cases of the Herpes Simplex in Spain (2016-2027)
Table 24: Sub-Type Specific cases of the Herpes Simplex in Spain (2016-2027)
Table 25: Sex- Specific Cases of the Herpes Simplex in Spain (2016-2027)
Table 26: Diagnosed Cases of the Herpes Simplex in Spain (2016-2027)
Table 27: Treatable Cases of the Herpes Simplex in Spain (2016-2027)
Table 28: Prevalent/Incident Cases of the Herpes Simplex in UK (2016-2027)
Table 29: Sub-Type Specific cases of the Herpes Simplex in UK (2016-2027)
Table 30: Sex- Specific Cases of the Herpes Simplex in UK (2016-2027)
Table 31: Diagnosed Cases of the Herpes Simplex in UK (2016-2027)
Table 32: Treatable Cases of the Herpes Simplex in UK (2016-2027)
Table 33: Prevalent/Incident Cases of the Herpes Simplex in Japan (2016-2027)
Table 34: Sub-Type Specific cases of the Herpes Simplex in Japan (2016-2027)
Table 35: Sex- Specific Cases of the Herpes Simplex in Japan (2016-2027)
Table 36: Diagnosed Cases of the Herpes Simplex in Japan (2016-2027)
Table 37: Treatable Cases of the Herpes Simplex in Japan (2016-2027)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Herpes Simplex in USD MM (2016-2027)
Table 42:7MM- Market Share Herpes Simplex by Therapies in USD MM (2016-2027)
Table 43:7MM- Market Sales of Herpes Simplex by Therapies in USD MM (2016-2027)
Table 44: United States-Market Size of Herpes Simplex in USD MM (2016-2027)
Table 45: United States-Market Share Herpes Simplex by Therapies in USD MM (2016-2027)
Table 46: United States-Market Sales of Herpes Simplex by Therapies in USD MM (2016-2027)
Table 47: Germany-Market Size of Herpes Simplex in USD MM (2016-2027)
Table 48: Germany-Market Share Herpes Simplex by Therapies in USD MM (2016-2027)
Table 49: Germany-Market Sales of Herpes Simplex by Therapies in USD MM (2016-2027)
Table 50: France-Market Size of Herpes Simplex in USD MM (2016-2027)
Table 51: France-Market Share Herpes Simplex by Therapies in USD MM (2016-2027)
Table 52: France-Market Sales of Herpes Simplex by Therapies in USD MM (2016-2027)
Table 53: Italy-Market Size of Herpes Simplex in USD MM (2016-2027)
Table 54: Italy-Market Share Herpes Simplex by Therapies in USD MM (2016-2027)
Table 55: Italy-Market Sales of Herpes Simplex by Therapies in USD MM (2016-2027)
Table 56: Spain-Market Size of Herpes Simplex in USD MM (2016-2027)
Table 57: Spain-Market Share Herpes Simplex by Therapies in USD MM (2016-2027)
Table 58: Spain-Market Sales of Herpes Simplex by Therapies in USD MM (2016-2027)
Table 59:UK-Market Size of Herpes Simplex in USD MM (2016-2027)
Table 60:UK-Market Share Herpes Simplex by Therapies in USD MM (2016-2027)
Table 61:UK-Market Sales of Herpes Simplex by Therapies in USD MM (2016-2027)
Table 62: Japan-Market Size of Herpes Simplex in USD MM (2016-2027)
Table 63: Japan-Market Share Herpes Simplex by Therapies in USD MM (2016-2027)
Table 64: Japan-Market Sales of Herpes Simplex by Therapies in USD MM (2016-2027)

List of Figures
Figure 1: Stages of Herpes infection
Figure 2: Clinical manifestations of Herpes infection
Figure 3: Risk factors associated with Herpes Simplex
Figure 4: Blisters
Figure 5: (a) Primary infection (b) Recurrent infection
Figure 6: Life Cycle of HSV infection
Figure 7: Establishment of primary infection
Figure 8: Prevalent Population of HSV in the 7MM (2016-2027)
Figure 9: 7MM Type-Specific Prevalent Population of HSV (2016-2027)
Figure 10: Prevalent Population of HSV in the United States (2016-2027)
Figure 11: Type-specific HSV Prevalence in the United States (2016-2027)
Figure 12: Diagnosed Cases of HSV in the United States (2016-2027)
Figure 13: Prevalent Population of HSV in Germany (2016-2027)
Figure 14: Type-specific HSV Prevalence in Germany (2016-2027)
Figure 15: Diagnosed Cases of HSV in Germany (2016-2027)
Figure 16: Prevalent Population of HSV in France (2016-2027)
Figure 17: Type-specific HSV Prevalence in France (2016-2027)
Figure 18: Diagnosed Cases of HSV in France (2016-2027)
Figure 19: Prevalent Population of HSV in Italy (2016-2027)
Figure 20: Type-specific HSV Prevalence in Italy (2016-2027)
Figure 21: Diagnosed Cases of HSV in Italy (2016-2027)
Figure 22: Prevalent Population of HSV in Spain (2016-2027)
Figure 23: Type-specific HSV Prevalence in Spain (2016-2027)
Figure 24: Diagnosed Cases of HSV in Spain (2016-2027)
Figure 25: Prevalent Population of HSV in the UK (2016-2027)
Figure 26: Type-specific HSV Prevalence in the UK (2016-2027)
Figure 27: Diagnosed Cases of HSV in the UK (2016-2027)
Figure 28: Prevalent Population of HSV in Japan (2016-2027)
Figure 29: Type-specific HSV Prevalence in Japan (2016-2027)
Figure 30: Diagnosed Cases of HSV in Japan (2016-2027)
Figure 31: Treatment Algorithm of HSV
Figure 32: Activation of Aciclovir
Figure 33: Unmet Needs of HSV
Figure 34: 7 Major Market Size of HSV Infection in USD Million (2016-2027)
Figure 35: Market Size of HSV Infection by Clinical manifestations in 7MM in USD Million (2016-2027)
Figure 36: 7MM Market Size of HSV Infection by Emerging Therapy in USD Million (2016-2027)
Figure 37: US Market Size of HSV in USD Million (2016-2027)
Figure 38: US Market Size of HSV by Clinical Manifestations in USD Million (2016-2027)
Figure 39: US HSV Infection Market by Treatment Types in USD Million (2016-2027)
Figure 40: US Market Size of HSV Infection by Emerging Therapy in USD Million (2016-2027)
Figure 41: Germany Market Size of HSV Infection in USD Million (2016-2027)
Figure 42: Germany Market Size of HSV Infection by Clinical Manifestations in USD Million (2016-2027)
Figure 43: Germany HSV Market by Treatment Types in USD Million (2016-2027)
Figure 44: Germany Market Size of HSV Infection by Emerging Therapy in USD Million (2016-2027)
Figure 45: France Market Size of HSV Infection in USD Million (2016-2027)
Figure 46: France Market Size of HSV Infection by Clinical Manifestations in USD Million (2016-2027)
Figure 47: France HSV Infection Market by Treatment Types in USD Million (2016-2027)
Figure 48: France Market Size of HSV Infection by Emerging Therapy in USD Million (2016-2027)
Figure 49: Italy Market Size of HSV Infection in USD Million (2016-2027)
Figure 50: Italy Market Size of HSV Infection by Clinical Manifestations in USD Million (2016-2027)
Figure 51: Italy HSV Infection Market by Treatment Types in USD Million (2016-2027)
Figure 52: Italy Market Size of HSV Infection by Emerging Therapy in USD Million (2016-2027)
Figure 53: Spain Market Size of HSV Infection in USD Million (2016-2027)
Figure 54: Spain Market Size of HSV Infection by Clinical Manifestations in USD Million (2016-2027)
Figure 55: Spain HSV Infection Market by Treatment Types in USD Million (2016-2027)
Figure 56: Spain Market Size of HSV Infection by Emerging Therapy in USD Million (2016-2027)
Figure 57: UK Market Size of HSV Infection in USD Million (2016-2027)
Figure 58: UK Market Size of HSV Infection by Clinical Manifestations in USD Million (2016-2027)
Figure 59: UK HSV Infection Market by Treatment Types in USD Million (2016-2027)
Figure 60: United Kingdom Market Size of HSV Infection by Emerging Therapy in USD Million (2016-2027)
Figure 61: Japan Market Size of HSV Infection in USD Million (2016-2027)
Figure 62: Japan Market Size of HSV Infection by Clinical Manifestations in USD Million (2016-2027)
Figure 63: Japan HSV Infection Market by Treatment Types in USD Million (2016-2027)
Figure 64: Japan Market Size of HSV Infection by Emerging Therapy in USD Million (2016-2027)
Figure 65: Market Drivers of HSV
Figure 66: Market Barriers of HSV
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Vical Therapeutics - Medivir
  • Maruho - GlaxoSmithKline
  • AiCuris - BioAlliance
  • Genocea Biosciences - Clinigen
  • Beech Tree Labs - Mylan
  • Squarex - Novartis
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll